biostudies-literatureUnknown12(2)Kittipibul VMerck Sharp & Dohme CorpMerck Sharp and Dohme United KingdomBayer AGBayer<h4>Aims</h4>The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM-HF and DAPA-HF trials.<h4>Methods</h4>Subgroups of VICTORIA participants (n = 5050) were generated to simulate PARADIGM-HF and DAPA-HF trial populations. The PARADIGM-HF-eligible population excluded participants not meeting left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and minimal dose criteria and those with high predicted probability of run-in failure. The DAPA-HF-eligible population excluded those nESC heart failure1479-1484https://www.ebi.ac.uk/biostudies/studies/S-EPMC11911596biostudies-literatureProjecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.PMC11911596McMullan CO'Connor CMMentz RJAnstrom KJEzekowitz JAKittipibul VVoors AVICTORIA Study GroupYoung RCorda SLam CSPButler JPonikowski PArmstrong PWfalseProjecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.<h4>Aims</h4>The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high-risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM-HF and DAPA-HF trials.<h4>Methods</h4>Subgroups of VICTORIA participants (n = 5050) were generated to simulate PARADIGM-HF and DAPA-HF trial populations. The PARADIGM-HF-eligible population excluded participants not meeting left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), and minimal dose criteria and those with high predicted probability of run-in failure. The DAPA-HF-eligible population excluded those n2025-01-01T00:00:00Z2025 Apr2026-06-01T19:02:26.916Z2025-04-04T03:02:15.615ZS-EPMC119115963943463110.1002/ehf2.15134